Clinical Trial Update: Efficacy and Safety of Allogenic Stem Cell Product(CARTISTEM®) for Osteochondral Lesion of Talus [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating allogenic stem cell product CARTISTEM for osteochondral lesions of the talus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chondral Lesion of the Talus
• Osteochondral Lesion of the Talus

Drugs mentioned

• CARTISTEM

Snippet

Sponsor: Hyundai Bioland Co., Ltd. | Conditions: Chondral or Osteochondral Lesion of Talus | Phase 3 | Status: COMPLETED